PerkinElmer releases assay kits for more effective biotherapeutics 

PerkinElmer has announced two ready-to-use HTRF and AlphaLISA no-wash assay kits designed to quickly and easily detect and quantify CHO HCP impurities during biopharmaceutical manufacturing.  

Recombinant therapeutic proteins, such as monoclonal antibodies, some vaccines and other biologics, must be free of residual host cell protein (HCP) impurities to prevent immunogenicity or reduced potency, stability or overall effectiveness of a drug. 

The kits 

These off-the-shelf kits are designed to deliver a streamlined workflow, a broader range and higher sensitivity than traditional multi-step ELISA assays. PerkinElmer says the kits are easily automatable and can be miniaturised to a small sample volume, significantly increasing throughput to 384-well plates. 

Official comments 

“The ability to quickly and easily detect, quantify and subsequently eliminate CHO HCP impurities during biopharmaceuticals manufacturing has continued to be a key challenge,” said Alan Fletcher, Senior Vice President of Life Sciences at PerkinElmer. “These innovative HTRF and AlphaLISA assay kits are designed to make this critical step more effective and efficient within existing workflows and contribute to quality control and successful biotherapeutics.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free